Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-1031 in Platinum-Resistant Ovarian Cancer
NCT03146663Phase 2Terminated
- Sponsor
- NuCana
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of gemcitabine monophosphate ProTide in ovarian cancer, sponsored by NuCana. Primary endpoint: Best Overall Response at 2 years. Started Sep 2017; status: terminated.
02
Drugs
gemcitabine monophosphate ProTide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03146663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146663.